Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q7939403> ?p ?o }
Showing triples 1 to 39 of
39
with 100 triples per page.
- Q7939403 subject Q8236086.
- Q7939403 subject Q8248770.
- Q7939403 abstract "Voglibose (INN and USAN, trade name Voglib, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. Voglibose delays the absorption of glucose thereby reducing the risk of macrovascular complications. Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company. Voglibose was first launched in 1994, under the trade name BASEN, to improve postprandial hyperglycemia in diabetes mellitus.Postprandial hyperglycemia (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal.There are three drugs which belong to this class, acarbose, miglitol and voglibose, of which voglibose is the newest. Voglibose has fewer side effects than both acarbose and miglitol. But acarbose has an edge over voglibose in terms of efficacy (FPG, PPHG, HBA1c).There are several trials supporting the use of voglibose in the management of PPHG. Also, it has been established that it is PPHG, not FPG, which is the marker of cardiovascular disorders associated with diabetes. So, controlling PPHG is imperative and voglibose is indicated for the management of PPHG.".
- Q7939403 atcPrefix "A10".
- Q7939403 atcSuffix "BF03".
- Q7939403 casNumber "83480-29-9".
- Q7939403 drugbank "DB04878".
- Q7939403 fdaUniiCode "S77P977AG8".
- Q7939403 iupacName "(1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol".
- Q7939403 pubchem "444020".
- Q7939403 thumbnail Voglibose_structure.svg?width=300.
- Q7939403 wikiPageWikiLink Q12206.
- Q7939403 wikiPageWikiLink Q271993.
- Q7939403 wikiPageWikiLink Q2992990.
- Q7939403 wikiPageWikiLink Q311213.
- Q7939403 wikiPageWikiLink Q338005.
- Q7939403 wikiPageWikiLink Q4734932.
- Q7939403 wikiPageWikiLink Q4926095.
- Q7939403 wikiPageWikiLink Q5572348.
- Q7939403 wikiPageWikiLink Q772735.
- Q7939403 wikiPageWikiLink Q8236086.
- Q7939403 wikiPageWikiLink Q824258.
- Q7939403 wikiPageWikiLink Q8248770.
- Q7939403 wikiPageWikiLink Q899133.
- Q7939403 atcPrefix "A10".
- Q7939403 atcSuffix "BF03".
- Q7939403 casNumber "83480".
- Q7939403 drugbank "DB04878".
- Q7939403 iupacName "-5".
- Q7939403 pubchem "444020".
- Q7939403 unii "S77P977AG8".
- Q7939403 type ChemicalSubstance.
- Q7939403 type Drug.
- Q7939403 type ChemicalObject.
- Q7939403 type Thing.
- Q7939403 type Q8386.
- Q7939403 comment "Voglibose (INN and USAN, trade name Voglib, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. Voglibose delays the absorption of glucose thereby reducing the risk of macrovascular complications. Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company.".
- Q7939403 label "Voglibose".
- Q7939403 depiction Voglibose_structure.svg.